18889881171
Kalkine 0
countryflagUS

Aida Pharmaceuticals Inc

Healthcare US AIDA

0.0002USD
-(-%)

Last update at 2025-05-21T20:00:00Z

Day Range

0.00020.0002
LowHigh

52 Week Range

0.00010.0003
LowHigh

Fundamentals

  • Previous Close 0.0002
  • Market Cap8.37M
  • Volume100
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA9.51M
  • Revenue TTM40.51M
  • Revenue Per Share TTM1.50
  • Gross Profit TTM 14.64M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly
Date 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Income before tax 2.02M 2.32M 1.51M 2.53M
Minority interest 7.87M 5.18M 3.57M 1.56M
Net income 2.74M 1.45M 1.47M 1.63M
Selling general administrative 8.91M 11.08M 13.98M 7.70M
Selling and marketing expenses - - - -
Gross profit 14.69M 15.56M 16.19M 10.82M
Reconciled depreciation - - - -
Ebit 4.19M 3.85M 1.63M 2.86M
Ebitda 6.06M 5.93M 3.32M -
Depreciation and amortization 1.87M 2.08M 1.69M -
Non operating income net other 0.00000M 0.00000M 0.00000M 0.00000M
Operating income 5.45M 3.94M 2.12M 2.86M
Other operating expenses 23.76M 25.71M 22.41M 0.00000M
Interest expense 2.02M 1.70M 1.10M 0.00000M
Tax provision - - - -
Interest income - - - -
Net interest income - - - -
Extraordinary items 0.00000M 0.00000M 0.00000M 0.00000M
Non recurring 0.00000M 0.00000M 0.00000M 0.00000M
Other items 0.00000M 0.00000M 0.00000M 0.00000M
Income tax expense 0.36M 0.17M 0.14M 0.15M
Total revenue 29.20M 29.64M 24.53M 15.65M
Total operating expenses 9.25M 11.63M 14.07M 12.79M
Cost of revenue 14.51M 14.08M 8.33M 4.82M
Total other income expense net 1.26M 0.09M 0.49M -0.32113M
Discontinued operations 0.00000M 0.00000M 0.19M 0.09M
Net income from continuing ops 4.32M 2.15M 1.36M 2.38M
Net income applicable to common shares 2.74M 1.45M 1.47M 1.63M
Preferred stock and other adjustments 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly
Date 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Total assets 62.73M 53.81M 42.66M 25.25M
Intangible assets 9.03M 9.47M 3.54M 0.77M
Earning assets - - - -
Other current assets 1.03M 0.26M 2.22M 4.65M
Total liab 41.54M 38.28M 32.37M 18.58M
Total stockholder equity 13.32M 10.35M 6.72M 5.11M
Deferred long term liab 0.00000M 0.00000M 0.00000M 0.00000M
Other current liab 4.60M 3.41M 5.19M 6.68M
Common stock 0.03M 0.03M 0.15M 0.02M
Capital stock - - - -
Retained earnings 7.33M 4.59M 3.14M 1.67M
Other liab 1.02M 2.09M 0.39M 0.17M
Good will 0.00000M 0.00000M 0.00000M 0.00000M
Other assets 0.20M 0.46M 3.64M 1.98M
Cash 8.40M 6.12M 3.13M 2.81M
Cash and equivalents - - - -
Total current liabilities 38.87M 34.38M 28.26M 17.31M
Current deferred revenue 0.14M 0.17M 0.11M -
Net debt 24.97M 23.44M 22.04M -
Short term debt 31.72M 27.63M 21.45M 0.00000M
Short long term debt 1.37M 0.00000M 0.00000M 0.00000M
Short long term debt total 33.37M 29.55M 25.17M -
Other stockholder equity 5.20M 5.20M 3.29M 0.00014M
Property plant equipment 17.02M 14.01M 12.84M 3.57M
Total current assets 36.28M 28.63M 22.41M 18.28M
Long term investments 0.21M 0.30M 0.22M 0.64M
Net tangible assets 4.29M 0.78M 3.18M 4.34M
Short term investments 10.55M 0.36M 0.00000M 0.00000M
Net receivables 10.83M 16.68M 13.71M 7.99M
Long term debt 1.65M 5.64M 3.72M 1.09M
Inventory 3.84M 2.81M 3.35M 2.83M
Accounts payable 2.55M 3.33M 1.62M 0.85M
Total permanent equity 0.00000M 0.00000M 0.00000M 0.00000M
Noncontrolling interest in consolidated entity 0.00000M 0.00000M 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests 0.00000M 0.00000M 0.00000M 0.00000M
Accumulated other comprehensive income 0.76M 0.53M 0.14M 0.00000M
Additional paid in capital 0.00000M 0.00000M 0.00000M 0.00000M
Common stock total equity 0.00000M 0.00000M 0.00000M 0.00000M
Preferred stock total equity 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings total equity 0.00000M 0.00000M 0.00000M 0.00000M
Treasury stock 0.00000M 0.00000M 0.00000M 0.00000M
Accumulated amortization 0.00000M 0.00000M 0.00000M 0.00000M
Non currrent assets other 0.21M 1.25M 3.65M 0.00000M
Deferred long term asset charges 0.00000M 0.00000M 0.00000M 0.00000M
Non current assets total 26.45M 25.18M 20.25M 0.00000M
Capital lease obligations 0.00000M 0.00000M 0.00000M 0.00000M
Long term debt total 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly
Date 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Investments -8.88689M -0.49056M -0.56132M -0.56132M
Change to liabilities -0.78504M 1.71M -0.92452M 0.13M
Total cashflows from investing activities -11.75074M -4.38110M -4.77996M -2.15941M
Net borrowings 3.85M 4.27M 0.50M 5.80M
Total cash from financing activities 5.02M 4.45M -1.16543M 4.98M
Change to operating activities 0.24M -0.65629M 2.88M -3.76778M
Net income 2.74M 1.45M 1.47M 1.63M
Change in cash 2.28M 2.99M 0.32M 0.29M
Begin period cash flow 6.12M 3.13M 2.81M -
End period cash flow 8.40M 6.12M 3.13M 2.81M
Total cash from operating activities 8.39M 2.66M 6.12M -2.52163M
Issuance of capital stock - - - -
Depreciation 1.87M 2.08M 1.69M 0.61M
Other cashflows from investing activities 1.06M 1.56M -3.53482M -5.38780M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory -1.03071M 0.54M 1.79M 0.10M
Change to account receivables 3.94M -4.63995M -2.71444M -2.00413M
Sale purchase of stock 0.00000M 0.00000M 0.00000M 0.00000M
Other cashflows from financing activities 5.02M 4.45M -1.16543M -1.78613M
Change to netincome 1.55M 1.85M 1.53M 1.28M
Capital expenditures 3.61M 2.97M 0.70M 1.16M
Change receivables 0.00000M 0.00000M 0.00000M 0.00000M
Cash flows other operating 0.00000M 0.00000M 0.00000M 0.00000M
Exchange rate changes 0.00000M 0.00000M 0.00000M 0.00000M
Cash and cash equivalents changes 0.00000M 0.00000M 0.00000M 0.00000M
Change in working capital 2.14M -2.73060M 2.37M -
Stock based compensation 1.58M 0.70M - -
Other non cash items 1.69M 2.36M 0.59M -
Free cash flow 4.78M -0.30777M 5.42M -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AIDA
Aida Pharmaceuticals Inc		 - -% 0.0002 - - 0.21 0.77 0.21 3.43
ZTS
Zoetis Inc		 -1.27 0.79% 160.17 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.64 2.42% 25.80 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 130.47 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.01 0.10% 14.34 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.

Aida Pharmaceuticals Inc

31 Dingjiang Road, Hangzhou, China, 310016

  • 86 571 8580 2712
  • Employees : 450

Key Executives

Name Title Year Born
Mr. Biao Jin Chairman and Chief Exec. Officer 1948
Ms. Lin Hui Chief Financial Officer and Principal Accounting Officer 1966
Mr. Yue Jun Jiang Chief of Investment Department and Sec. 1975
Mr. Qiu Jiajun Member of Compensation Committee and Director 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.